Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]-Ecopipam
NCT04881955Phase 1Completed
- Sponsor
- Emalex Biosciences
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ecopipam in Tourette syndrome (TS) and childhood-onset fluency disorder (COFD), sponsored by Emalex Biosciences. Primary endpoints: Amount of radioactivity excreted in urine, Cumulative radioactivity excreted in urine and 16 more. Started May 2021; status: completed.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)childhood-onset fluency disorder (COFD)
Beyond the preview
Go deeper on NCT04881955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881955.